T. Constantin

  • Hungary

  • 1365 Citations
  • 16 h-Index
If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where T. Constantin is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 16 Similar Profiles
Myositis Medicine & Life Sciences
Juvenile Arthritis Medicine & Life Sciences
Dermatomyositis Medicine & Life Sciences
Pediatrics Medicine & Life Sciences
Fabry Disease Medicine & Life Sciences
Antiphospholipid Syndrome Medicine & Life Sciences
Psoriatic Arthritis Medicine & Life Sciences
Rheumatology Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2002 2019

  • 1365 Citations
  • 16 h-Index
  • 45 Article
  • 1 Review article
2 Citations (Scopus)

Consensus-based recommendations for the management of juvenile localised scleroderma

Zulian, F., Culpo, R., Sperotto, F., Anton, J., Avcin, T., Baildam, E. M., Boros, C., Chaitow, J., Constantin, T., Kasapcopur, O., Knupp Feitosa De Oliveira, S., Pilkington, C. A., Russo, R., Toplak, N., Van Royen, A., Saad Magalhães, C., Vastert, S. J., Wulffraat, N. M. & Foeldvari, I., jan. 1 2019, In : Annals of the Rheumatic Diseases.

Research output: Article

Localized Scleroderma
Rheumatic Diseases
1 Citation (Scopus)

Etanercept treatment for extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or psoriatic arthritis: 6-year efficacy and safety data from an open-label trial

Foeldvari, I., Constantin, T., Vojinović, J., Horneff, G., Chasnyk, V., Dehoorne, J., Panaviene, V., Sušić, G., Stanevicha, V., Kobusinska, K., Zuber, Z., Dobrzyniecka, B., Nikishina, I., Bader-Meunier, B., Breda, L., Doležalová, P., Job-Deslandre, C., Rumba-Rozenfelde, I., Wulffraat, N., Pedersen, R. D. & 4 others, Bukowski, J. F., Vlahos, B., Martini, A. & Ruperto, N., máj. 23 2019, In : Arthritis Research and Therapy. 21, 1, 125.

Research output: Article

Open Access
Psoriatic Arthritis
Juvenile Arthritis

Intravenous dosing of tocilizumab in patients younger than two years of age with systemic juvenile idiopathic arthritis: Results from an open-label phase 1 clinical trial

Mallalieu, N. L., Wimalasundera, S., Hsu, J. C., Douglass, W., Wells, C., Penades, I. C., Cuttica, R., Huppertz, H. I., Joos, R., Kimura, Y., Milojevic, D., Rosenkranz, M., Schikler, K., Constantin, T. & Wouters, C., aug. 22 2019, In : Pediatric Rheumatology. 17, 1, 57.

Research output: Article

Open Access
Clinical Trials, Phase I
Juvenile Arthritis
Control Groups